Global & Italy Cancer Therapeutics Market to 2031

Italy has seen a steady rise in cancer cases in recent years. Based on GLOBOCAN data from the World Health Organization, approximately 430,000 new cancer cases were reported in the country in 2022, with breast cancer being the most frequently diagnosed, accounting for 13.2% of all cases. This was followed by colorectal cancer at 12.6% and lung cancer at 10.0%. That same year, cancer-related deaths reached around 190,000. Contributing to this trend is Italy’s aging population, which continues to grow due to declining birth rates and improved longevity. According to Eurostat’s 2024 data, Italy holds the distinction of having the oldest population in the European Union, with a median age exceeding 48 years. Nearly 24% of the population is over the age of 65—equivalent to roughly one in four citizens—and 7.7% are aged 80 or older. This demographic shift has led to a growing need for cancer treatments, particularly for age-related cancers such as breast, prostate, and lung cancer.

Italy's well-established healthcare infrastructure, coupled with increasing investments in medical research and healthcare spending, is expected to create significant growth opportunities in the cancer therapeutics sector. According to Knoema data, Italy’s healthcare expenditure per capita was $3,351 in 2021. This financial commitment supports the development and implementation of advanced cancer treatments, improving patient access to innovative therapies and driving overall market expansion.